Rare ALK Fusion Lung Cancer Shows Durable Response to First-Line Lorlatinib
A newly reported case shows that first-line lorlatinib achieved durable systemic and intracranial disease control in a patient with the ...
A newly reported case shows that first-line lorlatinib achieved durable systemic and intracranial disease control in a patient with the ...
Scientists report that TRI-611, a brain-penetrant molecular glue degrader, eliminates ALK fusion proteins and drives tumor regressions in preclinical models ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine